AN2 502998
Alternative Names: AN-15368; AN2-502998Latest Information Update: 19 Nov 2024
Price :
$50 *
At a glance
- Originator Anacor Pharmaceuticals; University of Georgia Research Foundation
- Developer AN2 Therapeutics; Anacor Pharmaceuticals; University of Georgia Research Foundation
- Class 1 ring heterocyclic compounds; 2 ring heterocyclic compounds; Amides; Amino acids; Antiparasitics; Organic boron compounds; Small molecules
- Mechanism of Action CPSF3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chagas disease